导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.38% | 2296/4773 |
| 近一周 | -2.17% | 1379/5462 |
| 近一月 | -4.25% | 2329/5421 |
| 近一季 | -6.68% | 2167/5209 |
| 近半年 | -0.86% | 1397/4920 |
| 近一年 | 2.34% | 2137/4366 |
| 近两年 | 47.50% | 1559/2954 |
| 近三年 | 31.35% | 1002/2253 |
| 成立以来 | 70.45% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.67% 3342/4961 |
13.16% 2050/5312 |
- - |
- - |
| 2025 | 20.28% 2135/4813 |
-0.45% 2254/3635 |
2.19% 1779/4076 |
18.00% 2376/4524 |
0.20% 2138/4813 |
| 2024 | 17.44% 688/3463 |
2.07% 822/2808 |
-0.29% 726/3014 |
17.14% 1263/3129 |
-1.49% 1726/3463 |
| 2023 | -7.98% 970/2656 |
3.82% 1118/2280 |
-3.77% 894/2385 |
-1.75% 573/2515 |
-6.25% 1692/2655 |
| 2022 | -16.29% 469/2207 |
-12.12% 574/1919 |
7.53% 459/2016 |
-12.78% 782/2113 |
1.57% 1217/2208 |
| 2021 | 2.07% 639/1822 |
-1.33% 470/1255 |
5.63% 797/1330 |
-3.91% 667/1466 |
1.92% 752/1822 |
| 2020 | - - |
- - |
- - |
18.10% 90/1164 |
13.89% 326/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 中泰沪深300增强A VS. 长安沪深300非周期A(740101) |